Klinische Wirkung von Crataegutt® bei Herzerkrankungen ischämischer und/oder hypertensiver Genese

Summary

A controlled double blind study was conducted in patients with heart disease of ischaemic and/or hypertensive origin (NYHA Stages II and III), to evaluate the efficacy of Crataegutt in comparison with an inactive placebo used as the control drug.

The total number of patients was 102, 14 were excluded for non-adherence to the test plan and a further eight dropped out. 80 patients were left for analysis. 35 of these belonged to group C and 45 to group P.

No deviations were noted in the overall clinical condition of the patients in groups C and P. Care was taken to maintain the equality between the two groups.

Concerning the general improvement and the improvement of cardiac function, group C was better with p < 0.01, and concerning the improvement of subjective symptoms with p < 0.001.

Considering individual subjective symptoms, group C was better with significant improvement of dyspnoea and palpitation at p < 0.01 and with significant improvement of cardiac edemas at p < 0.05.

No differences between the two groups were noted in the improvement of the ECG.

Side-effects were observed in one patient of group C, but were not severe enough to require discontinuation of the test.